
    
      To demonstrate the efficacy of secukinumab in subjects with moderate to severe plaque
      psoriasis based on the percentage of PASI 90 responder patients at Week 16 as compared to
      baseline Evaluation of onset of efficacy measured by the percentage of patient achieving PASI
      75 and PASI 90 at week 4 The efficacy of treatment using Investigator's Global Assessment
      modified 2011 (IGA mod 2011) at week 4 and week 16 Work productivity (measured with WPAI-PSO)
      at Week 16 Changes in quality of life measured with the Dermatology Life Quality Index (DLQI)
      at Week 16 Health assessment questionnaire -Disability index (HAQ-DI) in patients with
      psoriatic arthritis (PsA)
    
  